Top Section/Ad
Top Section/Ad
Most recent
Offer came as markets recovered and volatility fell
Abbott Laboratories plundered $20bn as it led a trio of drug companies which printed jumbo bonds as a deluge of supply in the dollar market ensured a red-hot end to the month.
Eight banks provided loan facility to company
More articles/Ad
More articles/Ad
More articles
-
KBRA expects to upgrade deal if merger with Orangetheory goes through -
US drug maker's stake in Haleon set to fall to 24%
-
Risk appetite is back and more deals coming, though one bad IPO would damage confidence in the recovery
-
More companies are getting ratings to woo bond investors
-
Europe's biggest IPO of the year so far gains traction with investors
-
After the listings in February delivered, Galderma adds fuel to the European IPO recovery
